Financial Post
🏢 Postmedia
📍 ON
May 21, 2026
· 5 min read
AI Analyzed
○ Unverifiable
View full audit trail →
Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026
Original article ↗ 🔒 Paywalled source — limited preview availableB.I.A.S. ANALYSIS
CENTER
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
-1.00 · LEFT
ML v2 (DistilBERT)
0.244 · RIGHT
Ensemble
0.122 · CENTER
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg -0.027
1,848 articles tracked
7-day bias trend
LcenterR
V.E.R.I.F.Y. has fact-checked this article.
Subscribe to see claim-by-claim verdicts and reasoning.
Subscribe to see claim-by-claim verdicts and reasoning.
Article Excerpt
This section is Partnership Content supplied by GlobeNewswire Article content Not intended for US and UK media Article content New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS® (zongertinib tablets) as an initial treatment option in HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC)1 Data for zongertinib monotherapy and in combination in other HER2-altered solid tumors, including breast, colorectal and esophageal cancers, shows encouraging early signals2-4 Updated data adds to the growing evidence base of obrixtamig in extensive‑…
Read full article at Financial Post ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.
Analyzed by
B.I.A.S.
V.E.R.I.F.Y.
L.O.C.A.L.
quick v1
Jun 1, 2026